Efficacy of AIN457 in Adults (18-65 Years) With Psoriatic Arthritis
Randomized, Double-blind Placebo-controlled Multi-center Proof-of-concept Study to Assess the Efficacy of AIN457 in Patients With Psoriatic Arthritis
研究概览
研究类型
注册 (实际的)
阶段
- 阶段2
联系人和位置
学习地点
-
-
-
Berlin、德国、12203
- Novartis Investigative Site
-
Hamburg、德国、22081
- Novartis Investigative Site
-
Hamburg、德国、22415
- Novartis Investigative Site
-
Herne、德国、44649
- Novartis Investigative Site
-
Muenchen、德国、80336
- Novartis Investigative Site
-
-
-
-
-
Glasgow、英国、G12 8TA
- Novartis Investigative Site
-
Leeds、英国、LS7 4SA
- Novartis Investigative Site
-
Newcastle upon Tyne、英国、NE2 4HH
- Novartis Investigative Site
-
-
-
-
DE
-
Amsterdamn、DE、荷兰、1100
- Novartis Investigative Site
-
-
KR
-
Meerssen、KR、荷兰、6231
- Novartis Investigative Site
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- A diagnosis of psoriatic arthritis
Exclusion Criteria:
- Patients with arthritis or ankylosing spondyitis
- Drug-induced psoriasis
- Male or female patients who plan to conceive during the time course of the study, or for 6 months after the administration of the second dose.
- Participation in any clinical trial within 4 weeks prior to initial dosing or longer.
- Previous use of immunosuppressive agents eg cyclosporine, without the necessary wash-out period
- History of severe allergy to food or drugs
- Positive TB test. Other protocol-defined inclusion/exclusion criteria may apply
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:双倍的
武器和干预
参与者组/臂 |
干预/治疗 |
---|---|
实验性的:AIN457 (2x 10mg/kg)
Each patient received 10 mg/kg AIN457 intravenously, on Day 1 and Day 22.
|
The investigational drug, AIN457 50 mg lyophilizate vials was prepared by Novartis.
Reconstitution of AIN457 with 1.2 mL SWFI produced a 47 mg/mL concentrate solution for infusion from which at least 1 mL was useable.
The AIN457 concentrate was diluted in 5% glucose bags for infusion through a 0.2 micron in-line filter.
|
安慰剂比较:Placebo
Each patient received 10 mg/kg of matching placebo intravenously, on Day 1 and Day 22.
|
Matching placebo to AIN457
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
---|---|---|
Percentage of ACR Responders Per Treatment at Week 6
大体时间:week 6
|
A participant was considered to be a responder according to the ACR20, 50 or 70 criteria if the participant had at least 20% 50% or 70% improvement in both the tender joint count and swollen joint count measures, and in at least 3 of the following 5 measures: patient's assessment of pain, patient's global assessment of disease activity, physician's global assessment of disease activity, Health Assessment Questionnaire (HAQ©) score, and/or C-reactive protein (CRP)
|
week 6
|
Percentage of PsARC Responders Per Treatment at Week 6
大体时间:week 6
|
Psoriatic Arthritis Response Criteria (PsARC) includes measures of tender and swollen joint counts, patient's assessment of pain, physician's and patient's global assessment of disease activity A subject is defined as a PsARC responder if, and only if, they have an improvement in two of the following four factors (with at least one factor being a joint count) and no worsening in the remaining factors: 1) Patient global assessment (0-100 VAS scale, improvement defined as decrease of at least 20 units) 2) Physician global assessment (0-100 VAS scale, improvement defined as decrease of at least 20 units) 3) Tender 78-joint count (improvement defined as decrease of at least 30%) 4) Swollen 76-joint count (improvement defined as decrease of at least 30%) |
week 6
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
---|---|---|
Percentage of Participants Who Achieved 20%, 50% or 70% Improvement as Measured by ACR Response Criteria
大体时间:Day 8 and 15, Weeks 6, 8, 12, 16 and 24
|
A participant was considered to be a responder according to the ACR20, 50 or 70 criteria if the participant had at least 20% 50% or 70% improvement in both the tender joint count and swollen joint count measures, and in at least 3 of the following 5 measures: patient's assessment of pain, patient's global assessment of disease activity, physician's global assessment of disease activity, Health Assessment Questionnaire (HAQ©) score, and/or C-reactive protein (CRP)
|
Day 8 and 15, Weeks 6, 8, 12, 16 and 24
|
Percentage of Participants Who Achieved PsARC Response
大体时间:Day 8 and 15, Weeks 6, 8, 12, 16 and 24
|
responder" defined as 20% or more improvement in at least 4 of 6 criteria: 1) swollen joint count, 2) tender joint count, 3) morning stiffness duration (low back), 4) current low back pain, 5) current peripheral joint pain, 6) patient global assessment A subject is defined as a PsARC responder if, and only if, they have an improvement in two of the following four factors (with at least one factor being a joint count) and no worsening in the remaining factors: 1) Patient global assessment (0-100 VAS scale, improvement defined as decrease of at least 20 units) 2) Physician global assessment (0-100 VAS scale, improvement defined as decrease of at least 20 units) 3) Tender 78-joint count (improvement defined as decrease of at least 30%) 4) Swollen 76-joint count (improvement defined as decrease of at least 30%)
|
Day 8 and 15, Weeks 6, 8, 12, 16 and 24
|
Mastricht Ankylosing Spondylitis Enthesis Score (MASES) Over Time Per Treatment
大体时间:Baseline and Day 8, 15 and weeks 6, 8, 12, 16 and 24
|
The MASES included assessments of 13 sites.
Enthesitis sites included in the MASES index are: 1st costochondral, 7th costochondral, posterior superior iliac spine, anterior superior iliac spine, iliac crest (all above was assessed bilaterally), 5th lumbar spinous process, proximal Achilles (bilateral).
The MASES score is defined as the total number of painful MASES entheses.
The score was derived as the sum of the 13 scores divided by 3 and the total range is 0 (no tenderness) to 13 (severe tenderness).
|
Baseline and Day 8, 15 and weeks 6, 8, 12, 16 and 24
|
Psoriatic Area and Severity Index (PASI) Score in Patients Over Time Per Treatment
大体时间:Baseline, Day 8, 15 and weeks 6, 8, 12, 16, 20 and 24
|
The PASI assessed the extent of psoriasis on four body surface areas (head, trunk and upper and lower limbs) and the degree of plaque erythema, scaling and thickness.
The PASI score accounted for the extent of body surface area affected by the erythema, scaling and thickness, and the severity of these measures.
The score ranged from 0 (no disease) to 72 (maximal disease).
|
Baseline, Day 8, 15 and weeks 6, 8, 12, 16, 20 and 24
|
SpA Research Consortium of Canada (SPARCC) Score Score in Patients Over Time Per Treatment
大体时间:Baseline, Day 8, 15 and weeks 6, 8, 12, 16 and 24
|
SPARCC evaluated 18 enthesis sites: medial and lateral epicondyle humerus, supraspinatus insertion, proximal Achilles, greater trochanter, medial and lateral condyl femur, insertion of plantar fascia, quadriceps insertion of patella, inferior pole of patella, and tibial tubercle.
SPARCC enthesis index is defined as the total number of painful entheses assessed at the SPARCC sites.
Total SI joint scores could range from 0 to 78, with a higher score indicating more signs of disease.
|
Baseline, Day 8, 15 and weeks 6, 8, 12, 16 and 24
|
Leeds Dactylitis Instrument (LDI) Score in Patients Over Time Per Treatment
大体时间:Baseline, Day 8, 15 and weeks 6, 8, 12, 16 and 24
|
The LDI basic measured the ratio of the circumference of the affected digit to the circumference of the digit on the opposite hand or foot, using a minimum difference of 10% to define a dactylitic digit.
The ratio of circumference was multiplied by a tenderness score, using a modification of LDI which was a binary score (1 for tender, 0 for non-tender).
If both sides were considered involved, the number was compared to data provided in a table.
This modification was referred to as LDI basic and was applied in this study.
The LDI required a tool to measure digital circumference and this tool was provided to the centers.
|
Baseline, Day 8, 15 and weeks 6, 8, 12, 16 and 24
|
Disease Activity Score 28 (DA28) in Patients Over Time Per Treatment
大体时间:Baseline, day 8, 15 and weeks 6, 8, 12, 16 and 24
|
The Disease Activity Score (DAS) is a combined index to measure disease activity in arthritic patients.
DAS28 is determined using the following variables: 28-joint counts (tender28 and swollen28), CRP, and the participant's general health (GH) Based on the patients global disease activity measured on a Visual Analogue Scale (VAS) of 100 mm (0 - 100).
Using the data from these variables, DAS28 is calculated using the following formula: DAS28 = 0.56*sqrt(TJC28) + 0.28*sqrt(SJC28) + 0.36*ln(CRP+1) + 0.014*GH + 0.96.
The calculation results in a DAS28 score from 0 to 10 indicating the current activity of the rheumatoid arthritis of the patient.
A DAS28 above 5.1 means high disease activity whereas a DAS28 below 3.2 indicates low disease activity.
Remission is achieved by a DAS28 lower than 2.6.
|
Baseline, day 8, 15 and weeks 6, 8, 12, 16 and 24
|
Pharmacokinetic (PK) of AIN457: Time to Reach the Maximum Concentration After Drug Administration (Tmax)
大体时间:Day 1 till end of the study (169)
|
On dosing days (Day 1 and Day 22) samples were taken at pre-dose (0 h), 2, 3, 4, 24.
After the first infusion samples were taken at Day 8 and Day 15.
After the second infusion samples were taken at Day 29, Day 43, Day 57, Day 71, Day 85, Day 113, Day 141, Day 169.
|
Day 1 till end of the study (169)
|
Pharmacokinetic (PK) of AIN457: Clearance of AIN457 After Single Dose Administration
大体时间:Day 1 till end of the study (169)
|
On dosing days (Day 1 and Day 22) samples were taken at pre-dose (0 h), 2, 3, 4, 24.
After the first infusion samples were taken at Day 8 and Day 15.
After the second infusion samples were taken at Day 29, Day 43, Day 57, Day 71, Day 85, Day 113, Day 141, Day 169.
|
Day 1 till end of the study (169)
|
Pharmacokinetic (PK) of AIN457: Terminal Elimination Half-life (T1/2)
大体时间:Day 1 till end of the study (169)
|
On dosing days (Day 1 and Day 22) samples were taken at pre-dose (0 h), 2, 3, 4, 24.
After the first infusion samples were taken at Day 8 and Day 15.
After the second infusion samples were taken at Day 29, Day 43, Day 57, Day 71, Day 85, Day 113, Day 141, Day 169.
|
Day 1 till end of the study (169)
|
Pharmacokinetic (PK) of AIN457: Observed Maximum Serum Concentration Following Drug Administration (Cmax)
大体时间:Day 1 till end of the study (169)
|
On dosing days (Day 1 and Day 22) samples were taken at pre-dose (0 h), 2, 3, 4, 24.
After the first infusion samples were taken at Day 8 and Day 15.
After the second infusion samples were taken at Day 29, Day 43, Day 57, Day 71, Day 85, Day 113, Day 141, Day 169.
|
Day 1 till end of the study (169)
|
PK of AIN457: Area Under the Serum Concentration-time Curve From Time Zero to the Time of Last Quantifiable Concentration (AUClast), Area Under the Serum Concentration-time Curve From Time Zero to (AUCinf)
大体时间:Day 1 till end of the study (169)
|
On dosing days (Day 1 and Day 22) samples were taken at pre-dose (0 h), 2, 3, 4, 24.
After the first infusion samples were taken at Day 8 and Day 15.
After the second infusion samples were taken at Day 29, Day 43, Day 57, Day 71, Day 85, Day 113, Day 141, Day 169.
|
Day 1 till end of the study (169)
|
Pharmacokinetic (PK) of AIN457: Volume of Distribution During the Terminal Phase Following Intravenous Elimination (Vz)
大体时间:Day 1 till end of the study (169)
|
On dosing days (Day 1 and Day 22) samples were taken at pre-dose (0 h), 2, 3, 4, 24.
After the first infusion samples were taken at Day 8 and Day 15.
After the second infusion samples were taken at Day 29, Day 43, Day 57, Day 71, Day 85, Day 113, Day 141, Day 169.
|
Day 1 till end of the study (169)
|
合作者和调查者
研究记录日期
研究主要日期
学习开始
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计)
研究记录更新
最后更新发布 (估计)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.
AIN457的临床试验
-
Novartis Pharmaceuticals终止类风湿关节炎美国, 德国, 希腊, 阿根廷, 巴西, 哥伦比亚, 捷克共和国, 多明尼加共和国, 危地马拉, 印度, 意大利, 日本, 大韩民国, 巴拿马, 葡萄牙, 南非
-
Novartis Pharmaceuticals终止狼疮性肾炎中国, 克罗地亚, 捷克语, 俄罗斯联邦, 火鸡, 澳大利亚, 西班牙, 泰国, 阿根廷, 美国, 丹麦, 希腊, 罗马尼亚, 德国, 大韩民国, 印度, 巴西, 日本, 秘鲁, 葡萄牙, 意大利, 台湾, 越南, 挪威, 哥伦比亚, 瑞典, 危地马拉, 法国, 菲律宾, 智利, 斯洛伐克, 墨西哥, 加拿大, 瑞士
-
Novartis Pharmaceuticals主动,不招人
-
Novartis Pharmaceuticals完全的类风湿关节炎哥伦比亚, 美国, 比利时, 火鸡, 泰国, 阿根廷, 意大利, 危地马拉, 印度, 日本, 巴拿马, 匈牙利, 英国, 墨西哥, 波多黎各, 加拿大
-
Novartis Pharmaceuticals招聘中
-
Academisch Medisch Centrum - Universiteit van Amsterdam...Novartis完全的